Alexander Lesokhin, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses the safety and efficacy of elranatamab in patients with multiple myeloma (MM) based on findings from two trials: MagnetisMM-1 and MagnetisMM-3 (NCT03269136; NCT04649359). In both studies, an overall response rate (ORR) of over 60% was observed, with a promising duration of response (DOR). Regarding adverse events (AEs), cytokine release syndrome (CRS) was the most frequent toxicity, although it was generally low grade. Immune effector cell-associated neurotoxicity syndrome (ICANS) occurred rarely and infections were a major non-hematologic toxicity. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть